Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals

Journal of Virology

Volumn 85, Issue 21, 2011, Pages 11502-11519

  Tomaras, Georgia D ^a   Binley, James M ^b   Gray, Elin S ^c   Crooks, Emma T ^b   Osawa, Keiko ^b   Moore, Penny L ^c   Tumba, Nancy ^c   Tong, Tommy ^b   Shen, Xiaoying ^b   Yates, Nicole L ^a   Decker, Julie ^b   Wibmer, Constantinos Kurt ^c   Gao, Feng ^a   Alam, S Munir ^a   Easterbrook, Philippa ^d   Karim, Salim Abdool ^e   Kamanga, Gift ^f   Crump, John A ^a,g   Cohen, Myron ^h   Shaw, George M ⁱ   Mascola, John R ^j   Haynes, Barton F ^a   Montefiori, David C ^a   Morris, Lynn ^c   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f KAMUZU CENTRAL HOSPITAL   (Malawi)

^g KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ Heerskink School of Medicine   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CENTROMERE ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; EPITOPE; GLYCAN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HISTONE ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; JO 1 ANTIBODY; LA ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADULT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BINDING SITE; BLOOD ANALYSIS; CLADISTICS; CONTROLLED STUDY; CROSS REACTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN QUATERNARY STRUCTURE; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; EPITOPES, B-LYMPHOCYTE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80055104586     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05363-11     Document Type: Article

References (111)

1. Abrahamyan, L. G., R. M. Markosyan, J. P. Moore, F. S. Cohen, and G. B. Melikyan. 2003. Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion. J. Virol. 77:5829-5836.
2. Barbas, C. F., III, et al. 1993. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J. Mol. Biol. 230:812-823.
3. Bibollet-Ruche, F., et al. 2006. Detection of novel neutralizing antibody responses to the membrane proximal external region (MPER) or gp41 following infection by HIV-1 subtypes A, B, C, D, F, G, H, CRF01, CRF02, or CRF11. Keystone Symp. X6, HIV Vaccines, Keystone, CO, 27 March to 2 April 2006.
4. Binley, J. M. 2009. Specificities of broadly neutralizing anti-HIV-1 sera. Curr. Opin. HIV AIDS 4:364-372.
5. Binley, J. M., et al. 2003. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J. Virol. 77:5678-5684.
6. Binley, J. M., et al. 1997. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J. Virol. 71:2799-2809.
7. Binley, J. M., et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of HIV-1 plasma samples from subtype B and C chronic infections. J. Virol. 82:11651-11668.
8. Binley, J. M., et al. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252.
9. Blish, C. A., M. A. Nguyen, and J. Overbaugh. 2008. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med. 5:e9.
10. Bonsignori, M., et al. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85:9998-10009.
11. Bunnik, E. M., L. Pisas, A. C. van Nuenen, and H. Schuitemaker. 2008. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J. Virol. 82:7932-7941.
12. Burton, D. R., et al. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236.
13. Burton, D. R., et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
14. Calarese, D. A., et al. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065-2071.
15. Cheng-Mayer, C., R. Liu, N. R. Landau, and L. Stamatatos. 1997. Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J. Virol. 71:1657-1661.
16. Choudhry, V., et al. 2007. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363:79-90.
17. Cohen, M. S., G. M. Shaw, A. J. McMichael, and B. F. Haynes. 2011. Acute HIV-1 infection. N. Engl. J. Med. 364:1943-1954.
18. Corti, D., et al. 2010. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5:e8805.
19. Crooks, E. T., et al. 2008. Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology 377:364-378.
20. Crooks, E. T., et al. 2007. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366:245-262.
21. Crooks, E. T., et al. 2005. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum. Antibodies 14:101-113.
22. D'Amelio, R., et al. 1992. Spectrotype of anti-gp120 antibodies remains stable during the course of HIV disease. J. Acquir. Immune Defic. Syndr. 5:930-935.
23. Davis, K. L., et al. 2009. Human immunodeficiency virus type 2 (HIV-2)/ HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J. Virol. 83:1240-1259.
24. Decker, J. M., et al. 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201:1407-1419.
25. Dhillon, A. K., et al. 2007. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 81:6548-6562.
26. Doores, K. J., and D. R. Burton. 2010. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 84:10510-10521.
27. Doria-Rose, N. A., et al. 2010. Breadth of human immunodeficiency virusspecific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84:1631-1636.
28. Fenyo, E. M., et al. 2009. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 4:e4505.
29. Forsman, A., et al. 2008. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J. Virol. 82:12069-12081.
30. Fouts, T. R., J. M. Binley, A. Trkola, J. E. Robinson, and J. P. Moore. 1997. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71: 2779-2785.
31. Gao, F., et al. 1996. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J. Virol. 70:1651-1667.
32. Gnanakaran, S., et al. 2010. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput. Biol. 6:e1000955.
33. Gorny, M. K., et al. 2005. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 79:5232-5237.
34. Gray, E. S., et al. 2011. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4' T cell decline and high viral load during acute infection. J. Virol. 85:4828-4840.
35. Gray, E. S., et al. 2009. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J. Virol. 83:11265-11274.
36. Gray, E. S., et al. 2011. Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizingantibody response in an HIV-1 subtype C-infected individual. J. Virol. 85:7719-7729.
37. Gray, E. S., et al. 2008. 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membraneproximal external region-neutralizing antibody response. J. Virol. 82:2367-2375.
38. Gray, E. S., et al. 2007. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 81:6187-6196.
39. Gray, E. S., et al. 2009. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J. Virol. 83:8925-8937.
40. Guenaga, J., et al. 2011. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS One 6:e16074.
41. Hariharan, K., P. L. Nara, L. A. Shabazz, J. A. McCutchan, and C. Y. Kang. 1994. Analysis of B cell repertoire specific to the neutralizing epitopes of glycoprotein 120 in HIV-infected individuals. AIDS Res. Hum. Retroviruses 10:1629-1637.
42. SHIVSF162P3. J. Virol. 75:1990-1995.
43. Haynes, B. F., et al. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908.
44. Hessell, A. J., et al. 2009. Effective, low titer, antibody protection against low dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15: 951-954.
45. Hessell, A. J., et al. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433.
46. Ba-L. J. Virol. 84:1302-1313.
47. Hioe, C. E., et al. 2010. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS One 5:e10254.
48. Kraft, Z., et al. 2007. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J. Virol. 81:6402-6411.
49. Labrijn, A. F., et al. 2003. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77:10557-10565.
50. Li, M., et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
51. Li, M., et al. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80: 11776-11790.
52. Li, Y., et al. 2007. Broad HIV-1 neutralization mediated by CD4 binding site antibodies. Nat. Med. 13:1032-1034.
53. Li, Y., et al. 2009. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83:1045-1059.
54. Liao, H. X., et al. 2009. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J. Virol. Methods 158:171-179.
55. Mascola, J. R. 2002. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20:1922-1925.
56. Mascola, J. R., and D. C. Montefiori. 2003. HIV-1: nature's master of disguise. Nat. Med. 9:393-394.
57. Mascola, J. R., and D. C. Montefiori. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28:413-444.
58. Mascola, J. R., et al. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
59. McMichael, A. J., P. Borrow, G. D. Tomaras, N. Goonetilleke, and B. F. Haynes. 2010. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10:11-23.
60. Mikell, I., et al. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7:e1001251.
61. Montero, M., N. E. van Houten, X. Wang, and J. K. Scott. 2008. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 72:54-84.
62. Moore, P. L., et al. 2006. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80:2515-2528.
63. Moore, P. L., et al. 2008. The C3-V4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J. Virol. 82:1860-1869.
64. Moore, P. L., et al. 2011. Potent and broad neutralization of HIV-1 subtype C viruses by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J. Virol. 85:3128-3141.
65. Moore, P. L., et al. 2009. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 5:e1000598.
66. Musich, T., et al. 2011. A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection. J. Virol. 85:2397-2405.
67. Muster, T., et al. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
68. Nandi, A., et al. 2010. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 396:339-348.
69. Nelson, J. D., et al. 2007. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J. Virol. 81:4033-4043.
70. O'Rourke, S. M., et al. 2010. Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J. Virol. 84:11200-11209.
71. Palker, T. J., et al. 1987. A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. Proc. Natl. Acad. Sci. U. S. A. 84:2479-2483.
72. Pantophlet, R., R. O. Aguilar-Sino, T. Wrin, L. A. Cavacini, and D. R. Burton. 2007. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology 364:441-453.
73. Parren, P. W., et al. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-8347.
74. Phogat, S., and R. Wyatt. 2007. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr. Pharm. Des. 13:213-227.
75. Richman, D. D., T. Wrin, S. J. Little, and C. J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100:4144-4149.
76. SHIVSF162P4. J. Virol. 84:3443-3453.
77. Rong, R., et al. 2007. Unique mutational patterns in the envelope α2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J. Virol. 81:5658-5668.
78. Rong, R., et al. 2009. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 5:e1000594.
79. Sanders, R. W., et al. 2002. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76:7293-7305.
80. Santiago, M. L., et al. 2008. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321:1343-1346.
81. Sather, D. N., et al. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
82. Sather, D. N., and L. Stamatatos. 2010. Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine 28(Suppl. 2): B8-B12.
83. Sattentau, Q. J., and J. P. Moore. 1995. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185-196.
84. Scanlan, C. N., J. Offer, N. Zitzmann, and R. A. Dwek. 2007. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446:1038-1045.
85. Scanlan, C. N., et al. 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of →2 mannose residues on the outer face of gp120. J. Virol. 76:7306-7321.
86. Scanlan, C. N., et al. 2003. The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. Adv. Exp. Med. Biol. 535:205-218.
87. Scheid, J. F., et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
88. Schulke, N., et al. 2002. Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J. Virol. 76:7760-7776.
89. Seaman, M. S., et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84:1439-1452.
90. Seaman, M. S., et al. 2007. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology 367:175-186.
91. Sharon, M., et al. 2003. Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure 11:225-236.
92. Shen, X., et al. 2010. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc. Natl. Acad. Sci. U. S. A. 107:5972-5977.
93. Shen, X., et al. 2009. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J. Virol. 83:3617-3625.
94. Simek, M. D., et al. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337-7348.
95. Stamatatos, L., M. Wiskerchen, and C. Cheng-Mayer. 1998. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. AIDS Res. Hum. Retroviruses 14:1129-1139.
96. Tomaras, G. D., et al. 2003. Identification of epitopes involved in escape from neutralizing antibody. Conf. Retroviruses Opportunistic Infect. (CROI), Boston, MA.
97. Tomaras, G. D., et al. 2008. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82:12449-12463.
98. Trkola, A., et al. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
99. Veazey, R. S., et al. 2003. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9:343-346.
100. Walker, L. M., and D. R. Burton. 2010. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22:358-366.
101. Walker, L. M., et al. 2010. High throughput functional screening of activated B cells from 4 African elite neutralizers yields a panel of novel broadly neutralizing antibodies, abstr. OA10.06 LB. AIDS Vaccine 10 Conf.
102. Walker, L. M., et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
103. Walker, L. M., et al. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6:e1001028.
104. Wei, X., et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
105. Wu, X., et al. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593-1602.
106. Wu, X., et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
107. Xiang, S. H., N. Doka, R. K. Choudhary, J. Sodroski, and J. E. Robinson. 2002. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res. Hum. Retroviruses 18:1207-1217.
108. Yuste, E., et al. 2006. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J. Virol. 80:3030-3041.
109. Zhou, T., et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817.
110. Zwick, M. B., et al. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:10892-10905.
111. Zwick, M. B., E. O. Saphire, and D. R. Burton. 2004. gp41: HIV's shy protein. Nat. Med. 10:133-134.